ABSTRACT
Conclusion:
This comparative study suggests that both propiverine hydrochlorid and trospium chloride are effective in the treatment of detrusor overactivity but as the expectance from anticholinergic drugs is minimum side effects, so trospium chloride is more advantageous in this view.
Results:
At the end of the treatment no difference was noted in the aspects of symptomatic and urodynamic improvement but dryness of mouth (34% vs. 11,8%, p=0,031) was statistically significant in propiverine group (p<0,05). Improvement in frequency (40% vs. 43,18%, p>0,05), urgency (55% vs. 63,2%, p>0,05), nocturia (73,03% vs. 77,02%, p>0,05) , urge incontinence (81,73%, vs. 78% p>0,05), episodes and number of ped usage per day (70,97% vs. 60,83%) decreased in group I and group II in a statistically significant manner (p<0,001). According to urodynamic parameters increase in volume at first sensation (46,80% vs. 29,41%, p>0,05), maximum cystometric capacity (21,10% vs. 10,5%, p>0,05) and disapperance of detrusor contractions (48,3% vs. 58,8%, p>0,05) were noted in both groups in a statistically significant manner (p<0,001). Improvement of quality of life scores in both groups (p<0,001) and no difference was found between group I and group II scores (p>0,05).
Materials and Methods:
63 women with urodynamically proven detrusor overactivity included to the prospective randomised controlled study. Group I (n=29) were given propiverine hydrochlorid and Group II (n=34) were given trospium chloride. After 8 week-treatment participants were clinically and urodynamically reevaluated. Outcomes of interest were patient perceived cure or improvement in symptoms, differences in number of incontinent episodes and number of voids in 24 hours, urodynamic measures of bladder function (volume at first sensation, maximum cystometric capacity, and presence of detrusor contractions) and side effects.
Objective:
The aim of this study is to compare the effectiveness of trospium chloride and propiverine hydrochlorid on detrusor overactivity in the view of symptoms, urodynamic parameters and quality of life scores.
